



Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New Powerful Class of HIV Viral Drug

Dr. Roger Kenneth Hershline PhD MD, Chairman and Founder of CureHIV.us, agreed to provide samples of Global Humanceuticals, Inc's NIAID#11039, a new powerful class of anti-HIV drug to clinical researchers. The drug is able de-activates the virus even if diluted nearly a billion times.

Hilton Head Island, SC, September 09, 2007 --(PR.com)-- At approximately 3:21 PM today, Dr. Roger Kenneth Hershline PhD MD, Chairman and Founder of CureHIV.us, agreed to act as a conduit to provide samples of Global Humanceuticals, Inc's., new extremely safe, potent and stable drug candidate to profit, non-profit, academic, government, non-government, U.S. and foreign institutions, organizations, and corporations, under mutual agreements, contracts or partnerships, to spur theoretical, objective, mechanistic, developmental or clinical research. This unique new chemical entity or potentially new medication, is referred to as compound NIAID #11039. However, this invention has already received a patent called: Antiviral Composition, U.S. patent number: 6,821,958 on November 23, 2004. The World International Patent Organization published the International Application Number as PCT/US2005/039528 on November 5, 2006.

“This gift is intended to extend technology that no one else posses on this planet,” stated Dr. Hershline. “Already, Chinese scientist are very interested.” Dr. Hershline hosted Session V at the World Aids Day Conference China Dec 1 to Dec 3, 2006, to initially present data an NIAID#11039. There was, unfortunately, a communication error from the National Institute of Health (NIH of the United States) to Dr. Hershline, which prevented presentation of test results.

The compound has a non-toxic alpha-glucose backbone, obtained from an abundant natural source. The backbone is chemically bi-substituted in a random fashion, by a newly patented reaction. “The substitution groups are two different sulfur based viral de-activating groups that work together to provide inhibition at concentrations of one pico-Molar. This active concentration is equivalent to diluting a 1% solution one million times and still remain active.

The compound is highly safe and stable at ambient conditions. The random substitutions are intended to prevent the virus from escaping de-activation thru mutation. “Global Humanceuticals, Inc.'s NIAID #11039 is the first drug designed to prevent the development of resistance, the biggest nightmare in HIV treatment,” Stated Dr. Hershline.

“I think we have to talk in terms of a cure for HIV. I want to cure HIV, not propagate it. I don't want to play with this lethal virus, I want to kill it! I want to cure this disease, that is why my foundation is called CureHIV.us. I truly believe a cure for HIV is possible. As a physicians, and a medical researchers, we must believe that someday we will cure all disease. That belief keeps up our spirits - please do not take that away,” concluded Dr. Hershline.

Interested parties can contact Dr. Roger Kenneth Hershline PhD MD, at CureHIV.us Headquarters by email: Roger@CureHIV.us , mail P.O. Box 23467, Hilton Head Is., SC, 29925, by fax: 843-342-5924,



phone: 843-342-5900. Direct to Dr. Hershline: 843-683-3683.

###



Contact Information:

CureHIV

Guy Foulke

843-422-1950

roger@CureHIV.us

www.CureHIV.us

Guy Foulke Board Member CureHIV and owner of MAPTech Packageing

Online Version of Press Release:

You can read the online version of this press release at: <http://www.pr.com/press-release/51573>

News Image:

